| Company Name | AbbVie Biopharmaceuticals GmbH Taiwan Branch |
|---|---|
| Protocol Number | H19-940 |
| Title of Study | Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD) |
| Primary Objective | To describe the multidimensional burden of disease, treatment patterns, and health care resource utilization in adolescent and adult patients with moderate to severe AD. |
| Number of Sites | 2 |
| Period of Study | From：2020/01/01 to：2021/12/31 |
| Number of Patients | 25人 |
| IRB Approval Date | NTUH: 2020/02/19 CSMUH: not yet |
| Publication Plan / Date |
